Barry woke up with a tickly throat and a tad off colour. After seeing his health premium renewal, that turned into a full-blown flu. Pic: Getty Images
- The country’s biggest private health fund says it’s in good health, despite “affordability pressures”
- EBR expects a US reimbursement decision to double patient volumes
- Impedimed’s chairman says “disappointing” share price masks the medtech’s progress
Medibank Private (ASX:MPL) has grown its mainstay resident health insurance arm, despite cash-strapped consumers shopping around for the elusive mix of lower premiums and better coverage.
There’s only so much a meerkat can do, mind you.
At the fund’s AGM this morning, CEO David Koczkar reported “positive momentum” in the first four months of the 2026-27 year.
“Competitive conditions remain in line with the fourth (June) quarter of 2025-26,” he said.
“Ongoing affordability pressures continue to see customers seek value, contributing to elevated switching and aggregator activity.
“Against this backdrop, we have maintained our disciplined approach, with resident policyholders growing over the first four months of 2026-27.”
In August, Medibank reported an underlying net profit of $636.8 million in the year to June 2026, up 2.9%. The fund paid a record $6.9 billion in claims.
At the time, the company guided to a “broadly consistent margin” for its mainstay health insurance arm, with “disciplined” market share growth.
Koczkar today said claims experience remained consistent with management’s expectations and “supportive of our 2026-27 resident private health insurance gross margin outlook”.
However, profitability relied on the degree of allowable premium increases from April 1.
That’s otherwise known as the usual annual bun fight between government and the sector.
“In the context of broader economic conditions, we are monitoring utilisation trends across more discretionary extras services and the drivers of revenue mix,” Koczkar said.
“In non-resident health insurance, the rate of policy unit decline has moderated in the first four months of 2026-27 relative to the fourth quarter of 2025-26.”
Growing older and sicker
Medibank chairman Mike Wilkins intoned that while Australia had a strong health system, it was under growing strain.
“An ageing population, chronic disease, workforce shortages, rising costs and unequal access are reshaping demand,” he said.
“Over the past 50 years, Australia’s population has nearly doubled, as has the proportion of people aged 65 and over.”
He said people on average were living eleven years longer – often in ill health.
About 60% of adults live with at least one chronic condition.
As Deborah Harry sang back in 1979: Die Young, Stay Pretty. But that’s ironic given the punk songstress is pushing into her 80s and looks pretty fab.
Koczkar said that following the government’s bulk billing reforms to encourage docs to do so, the proportion of ‘no gap’ GP clinics in Medibank’s network grew to 56%.
“But more needs to be done to make primary care better able to support people with chronic conditions.”
He claimed one in four people (or a family member) had delayed a GP visit because of cost.
Meanwhile, Koczkar said it was “remarkable” how much of the health system relied on “analogue and disconnected” processes.
“Technology and AI present a huge opportunity to help solve the challenges of the future while better connecting the health system of today,” he said.
“But we also know that technology alone won’t solve these challenges, because health is and always will be fundamentally human.”
Phew!
EBR awaits crucial US coverage ruling
Innovative leadless pacemaker developer EBR Systems (ASX:EBR) is girding for a US reimbursement decision that could double potential patient coverage for its Wise device.
EBR expects a proposed National Coverage Determination (NCD) in early December, with a final decision expected in March 2027.
US reimbursement is mind-bogglingly complex, so we’ll hand over the explanatory duties to EBR’s chief corporate development officer, Dr Andrew Shute.
“The outcome will provide uniform national coverage for us,” he told Bell Potter’s healthcare conference this week.
“Just to give some context, 80% of the eligible [patient] population are aged over 65 years, meaning they’re Medicare eligible.
“These are split roughly evenly amongst traditional Medicare coverage and Medicare Advantage.
“While we have coverage for those covered by traditional Medicare, those covered by Medicare Advantage plans really require prior authorisation,” Shute said.
“The nature of seeking prior authorisation is often challenging and they also have higher rejection rates.”
He said that by providing five years of uniform national coverage, an NCD would bypass payment hurdles for physicians.
“Essentially it’s going to double our patient base.”
Shute said medtech giant Medtronic received an NCD for a renal denervation system, used to treat hypertension.
“They saw a doubling of their weekly procedure volume (and) it’s not unreasonable to expect a similar impact for us.”
EBR is in the early stages of its US commercial rollout of the WiSE device, which has been slower than the company first anticipated.
Impedimed promises better times ahead
Speaking of US-focused medtechs, lymphoedema detection device play ImpediMed (ASX:IPD) insists it’s in turnaround mode in the wake of an 88% year-to-date share slump.
“The board recognises that we are all disappointed with the current share price which significantly undervalues the business,” chairman Christine Emmanuel-Donnelly told today’s AGM.
She said despite the share lull, the past year had been one of “significant transition and important progress” for the company.
CEO Dr Parmjot Bains departed mid-year after a two-year stint, to be replaced with non-executive director Erik Anderson.
Emmanuel-Donnelly said “market conditions remain challenging and our share price performance has been disappointing”.
But “we have continued to strengthen the foundations of the business, focus on commercial execution and position ImpediMed for the next phase of growth”.
Impedimed’s revenue grew by 15% in the year to June 2026, with US reimbursement coverage for its SOZO device for breast cancer-related lymphoedema expanding to 95%.
She said management expected to deliver around $5 million in annualised cost savings, “with benefits already emerging in our financial results”.
The company plans to drive growth by expanding SOZO’s usage to weight management and fluid status monitoring in heart health.
EMvision pockets study funding
The developer of a portable stroke imaging tool, EMvision Medical Devices (ASX:EMV) has pocketed a $306,750 progress payment from the Cooperative Research Centres Projects (CRC-P) program.
The payment pertains to EMvision’s regional benefits study.
As its name suggests, the study aims to generate clinical evidence to support regional and rural use of EMvision’s Emu bedside scanner.
The study involves placing Emu devices in regional hospitals without ready access to CT imaging.
“The objective is to show that [Emu] can speed up stroke diagnosis and support earlier triage, transfer or treatment decisions for patients who would otherwise face lengthy transfers.”
EMvision targets an initial 400 Australian regional and remote hospitals and more than 1300 US critical access facilities.
“Similar models of care and similar diagnostic challenges are found across rural communities worldwide.”
The latest payment means EMvision has now banked $1.85 million of a total $3m CRC-P grant.
The company is carrying out the study with partners the Australian Stroke Alliance, Titan Pre-Hospital Innovation and South Australia’s Rural Support Service.
Pending ethics approval, EMvision plans to start the study in the second half of calendar 2027.
The company notes that stroke care access is “markedly unequal” across our broad land. Patients in regional hospitals are 76% less likely to receive treatment in a stroke unit than those in metro hospitals.
Thanks anti-vaxxers, measles is back
In a new low for US public health, global health officials have declared measles is no longer considered eliminated in the vaccine-sceptic nation.
That reverses a 2000 declaration that the highly contagious viral disease had been eliminated in the US.
According to the health newsletter Stat, the reversal marks an “embarrassing and avoidable backslide in the country’s basic public health standing”.
A committee of the Pan American Health Organisation issued the decision. This body is part of the World Health Organisation (WHO).
According to the Mayo Clinic, measles is one of the most contagious human illnesses.
An infected person can spread it to roughly 90% of unprotected people with whom they come into close contact.
Australia was granted WHO measles elimination status in 2014 – and still holds that accolade.
But post-COVID case numbers have ticked up.
The superspreaders are, you guessed it, visitors returning from overseas countries where outbreaks have occurred.
At Stockhead we tell it as it is. While EBR Systems and EMvision are Stockhead advertisers, the companies did not sponsor this column.